Drugs / Trodusquemine
Trodusquemine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00806338 | Nov 2008 → Apr 2009 | obesity disorder, type 2 diabetes mellitus | Genaera Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00509132 | May → Oct 2007 | obesity disorder | Genaera Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00606112 Comparator | Jan → Jun 2008 | obesity disorder, type 2 diabetes mellitus | Genaera Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trodusquemine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00806338 ↗ |
| Known as | MSI-1436 | “Different amounts of trodusquemine (MSI-1436) will be given to each volunteer group throughout the study.” NCT00606112 ↗1“Trodusquemine (MSI-1436)” NCT00806338 ↗ |
| Known as | Trodusquemina | ChEMBL registry synonym — accepted as the source's own label CHEMBL508583 ↗ |
| Known as | TRODUSQUEMINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL508583 ↗ |
| Modality | Small molecule | — CHEMBL508583 ↗ |
| Route | Intravenous | “single intravenous (through a vein) doses of trodusquemine” NCT00509132 ↗ |